Editor's Note: MannKind's PDUFA date is July 15th -- it was accidentally noted as June 15th. The Fool regrets the error.
MannKind's (NASDAQ: MNKD ) PDUFA date is July 15, so we'll be watching carefully to see whether the Food and Drug Administration will approve its inhaled insulin Afrezza.
This isn't the first time the drug-device has been up for approval. The company changed the device portion of Afrezza before the last review, which led the FDA to request more clinical trials. MannKind ran the trials, which both came back positive.
If approved, Afrezza will compete with injected mealtime insulins from Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ) . One of the clinical trials showed that Afrezza was non-inferior -- clinical-trial lingo for the same or better -- to Novo Nordisk's Novolog.
Slam-dunk approval, then?
Not so fast.
While the FDA advisory committee recommended the agency approve the drug, the agency has the final say and doesn't always follow the panel's advice. Considering that the FDA's briefing documents sent to the committee trended toward the negative side, an approval isn't a foregone conclusion.
Watch the following video for more thoughts on the potential approval of MannKind's Afrezza from senior biotech specialist Brian Orelli and health-care analyst David Williamson.
Multibagger potential, no binary event required
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! You don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.